The biotech sector, as measured by the XBI ETF, is down more than 2% in the current session, continuing a recent trend of weakness. There is no single, identifiable news event or sector-wide catalyst in today's market session that would account for this significant downward move. The decline appears to be driven by broader market sentiment or a continuation of negative momentum from earlier in the week, rather than a specific, actionable news item within the biotech industry.